(Q24244070)

https://api.crossref.org/works/10.1002%2F14651858.CD005445

Hepatitis C in adults and adolescents with hemophilia: a randomized, controlled trial of interferon alfa-2b and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

Modulation of hepatitis C virus quasispecies heterogeneity by interferon-alpha and ribavirin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C relapsing after interferon monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

Treatment with ribavirin+alpha interferon in HCV chronic active hepatitis non-responders to interferon alone: preliminary results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

Recent advances: hepatology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

High prevalence of cutaneous reactions to interferon alfa plus ribavirin combination therapy in patients with chronic hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Effects of adding ribavirin to interferon to treat chronic hepatitis C infection: a systematic review and meta-analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

A pilot study of ribavirin therapy for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Pilot study of ribavirin and interferon-beta for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Hepatitis C: the clinical spectrum of disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Natural history of hepatitis C

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: results of a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

r-Interferon alfa-2b/ribavirin combined therapy followed by low-dose r-interferon alfa-2b in chronic hepatitis C interferon nonresponders.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

The impact of diagnosis of hepatitis C virus on quality of life.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Effects of ribavirin on intrahepatic and extrahepatic expression of hepatitis C virus in interferon nonresponsive patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Quantifying heterogeneity in a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Methods for combining randomized clinical trials: strengths and limitations.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Teratogenic effects of ribavirin on hamster and rat embryos

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Changes in hepatitis C virus antigen in liver with antiviral therapy.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Ribavirin treatment for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Meta-analysis in clinical trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Reduction of relapse rates by 18-month treatment in chronic hepatitis C. A Benelux randomized trial in 300 patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Interferon alpha-2B and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon alpha therapy: a randomized trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Decisions, decisions, decisions

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Treatment of hepatitis C virus infection with ribavirin in kidney transplant patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Prophylaxis against HCV recurrence after liver transplantation: effect of interferon and ribavirin combination.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Hepatitis C recurrence in liver transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Treatment of recurrent hepatitis C virus infection after liver transplantation with interferon and ribavirin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Efficacy of 5 MU of interferon in combination with ribavirin for naïve patients with chronic hepatitis C virus: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

The pattern of response to interferon alpha (alpha-IFN) predicts sustained response to a 6-month alpha-IFN and ribavirin retreatment for chronic hepatitis C. TVVH Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Evaluation of long-term efficacy of interferon alpha-2b and ribavirin in combination in naive patients with chronic hepatitis C: an Italian multicenter experience. Ribavirin-Interferon in Chronic Hepatitis Italian Group Investigators.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Combined treatment of relapse of chronic hepatitis C with high-dose alpha2b interferon plus ribavirin for 6 or 12 months.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Early addition of ribavirin to interferon in chronic hepatitis C not responsive to interferon monotherapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Daily or three times a week interferon alfa-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Daily or three times per week interferon alpha-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C not responding to previous interferon alone.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

High doses of interferon in combination with ribavirin are more effective than the standard regimen in patients with HCV genotype 1 chronic hepatitis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

A randomized trial of consensus interferon in combination with ribavirin as initial treatment for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Ribavirin in the treatment of chronic hepatitis C unresponsive to alfa interferon

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Ribavirin therapy in chronic delta hepatitis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Increase in hepatic iron stores following prolonged therapy with ribavirin in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Effect of ribavirin on virus load and quasispecies distribution in patients infected with hepatitis C virus

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Sarcoidosis associated with interferon-alpha therapy for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Interferon-alpha plus ribavirin in chronic hepatitis C resistant to previous interferon-alpha course: results of a randomized multicenter trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

A randomized trial of ribavirin and interferon-alpha vs. interferon-alpha alone in patients with chronic hepatitis C who were non-responders to a previous treatment. Multicenter Study Group under the coordination of the Necker Hospital, Paris, Franc

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Improved correlation between multiple mutations within the NS5A region and virological response in European patients chronically infected with hepatitis C virus type 1b undergoing combination therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Hepatitis C virus infection: quality of life and side effects of treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

High-dose interferon plus ribavirin in chronic hepatitis C not responding to recombinant alpha-interferon.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Pilot dose-finding trial on interferon alpha in combination with ribavirin for the treatment of chronic hepatitis C in patients not responding to interferon alone

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Clinical comparison of high-dose interferon-alpha2b with or without ribavirin for treatment of interferon-relapsed chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Comparative effects of different doses of ribavirin plus interferon-alpha2b for therapy of chronic hepatitis C: results of a controlled, randomized trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Interferon-alpha2b induction treatment with or without ribavirin in chronic hepatitis C: a multicenter, randomized, controlled trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Improved response to ribavirin interferon combination compared with interferon alone in patients with type 4 chronic hepatitis C without cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Efficacy of a short-term ribavirin plus interferon alpha combination therapy followed by interferon alpha alone in previously untreated patients with chronic hepatitis C: a randomized multicenter trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

High rate of long-term virological response after a 1-year course of interferon +/- ribavirin in chronic hepatitis C relapsers. Results of a 191 patients randomized trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Interferon alpha with ribavirin for the treatment of chronic hepatitis C in non-responders or relapsers to interferon monotherapy.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

A randomized trial of high-dose interferon alpha-2b, with or without ribavirin, in chronic hepatitis C patients who have not responded to standard dose interferon.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Cost-effectiveness analysis of therapeutic strategies for patients with chronic hepatitis C previously not responding to interferon.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Induction interferon and ribavirin for re‐treatment of chronic hepatitis C patients unresponsive to interferon alone

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Combination therapy with interferon alpha and ribavirin for chronic hepatitis C virus infection in thalassaemic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Ribavirin and interferon-alpha combination therapy vs interferon-alpha alone in the retreatment of chronic hepatitis C: a randomized clinical trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Interim analysis of a randomized controlled trial of combination of ribavirin and high dose interferon-alpha in interferon nonresponders with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Interferon plus ribavirin in chronic hepatitis C non-responders to recombinant alpha-interferon.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

The safety and tolerability of daily infergen plus ribavirin in the treatment of naíïve chronic hepatitis C patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Retreatment with interferon and ribavirin vs interferon alone according to viraemia in interferon responder-relapser hepatitis C patients: a prospective multicentre randomized controlled study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Combination of ribavirin and interferon-alfa surpasses high doses of interferon-alfa alone in patients with genotype-1b-related chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in germany: a 20-year multicenter study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Effect of ribavirin on dynamics of hepatitis C viremia in interferon alpha-treated patiens with response or no response

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Effect of combined interferon-alpha induction therapy and ribavirin on chronic hepatitis C virus infection: a randomized multicentre study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Treatment with interferon-alpha2a alone or interferon-alpha2a plus ribavirin in patients with chronic hepatitis C previously treated with interferon-alpha2a. CONSTRUCT Group.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Comparison of 3 quantitative HCV RNA assays--accuracy of baseline viral load to predict treatment outcome in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Long-term re-treatment with interferon and ribavirin combination therapy in patients with chronic hepatitis C who are non-responders to interferon alone: a preliminary study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

A randomized, controlled trial to determine whether continued ribavirin monotherapy in hepatitis C virus-infected patients who responded to interferon-ribavirin combination therapy will enhance sustained virologic response

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Treatment of hepatitis C and anemia in human immunodeficiency virus-infected patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Molecular mechanisms of action of ribavirin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Changes in serum hepatitis C virus RNA in interferon nonresponders retreated with interferon plus ribavirin: a preliminary report

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Treatment of hepatitis C virus genotype 4-related cirrhosis: ribavirin and interferon combination compared with interferon alone

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Outcome of long-term ribavirin therapy for recurrent hepatitis C after liver transplantation.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Treatment of patients with chronic hepatitis C not responding to interferon with high-dose interferon alpha with or without ribavirin: final results of a prospective randomized trial. Austrian Hepatitis Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

High sustained response rate in patients with histologically mild (low grade and stage) chronic hepatitis C infection. A randomized, double blind, placebo controlled trial of interferon alpha-2b with and without ribavirin.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Interferon versus ribavirin plus interferon in chronic hepatitis C previously resistant to interferon: a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Treatment of chronic hepatitis C in patients who failed interferon monotherapy: effects of higher doses of interferon and ribavirin combination therapy. The Virginia Cooperative Hepatitis Treatment Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Effect of retreatment with interferon alone or interferon plus ribavirin on hepatitis C virus quasispecies diversification in nonresponder patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Cost effectiveness of combination therapy for hepatitis C: a decision analytic model

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Retreatment with interferon-alpha and ribavirin in primary interferon-alpha non-responders with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Retreatment of hepatitis C non-responsive to interferon. A placebo controlled randomized trial of ribavirin monotherapy versus combination therapy with Ribavirin and Interferon in 121 patients in the Benelux [ISRCTN53821378]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Increased hepatic iron deposition resulting from treatment of chronic hepatitis C with ribavirin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Interferon-alpha alone versus interferon-alpha plus ribavirin in patients with chronic hepatitis C not responding to previous interferon-alpha treatment.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Interferon-alpha (IFN alpha) daily dose versus IFN alpha plus ribavirin for treatment-naive chronic hepatitis c patients infected by genotype 1b.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

Ribavirin: a possible alternative for the treatment of chronic non-A, non-B hepatitis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005445

7 January 2021

10.1002/14651858.CD005445

Identifiers

DOI

0 references

Fatcat ID

release_57rxmdnegbdbva4ssqi4cb3v5e

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/57rxmdnegbdbva4ssqi4cb3v5e

24 November 2022